For the year ending 2025-12-31, PTHS made $16,795K in revenue. -$43,319K in net income. Net profit margin of -257.93%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 16,795 | |||
| Cost of goods sold | 3,988 | |||
| Selling, general and administrative | 42,453 | |||
| Research and development | 1,228 | |||
| Amortization of intangible assets | 1,556 | |||
| Total operating expenses | 49,225 | |||
| Operating loss | -32,430 | |||
| Interest expense | 3,012 | |||
| Impairment of intangible assets | 285 | |||
| Change in fair value of convertible debt | -14,984 | |||
| Interest income and other income | 5 | |||
| Total other (expense) income | -18,276 | |||
| Net loss before provision for income taxes | -50,706 | |||
| Provision for income taxes | -7,387 | |||
| Net loss | -43,319 | |||
| Basic EPS | -23.04 | |||
| Diluted EPS | -23.04 | |||
| Basic Average Shares | 1,880,498 | |||
| Diluted Average Shares | 1,880,498 | |||
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)